We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Clotting Factor Plays Critical Roll in Tumor Angiogenesis

By LabMedica International staff writers
Posted on 10 Nov 2009
A variant form of the blood clotting protein "Tissue Factor" or TF has been identified as a key modulator of angiogenesis, and may serve as a target for chemotherapy aimed at denying tumors the increased blood supply they require for growth and metastasis.

Investigators at the University of Cincinnati (OH, USA) in collaboration with colleagues at Leiden University (The Netherlands) worked with a modified form of TF known as alternatively spliced Tissue Factor or asTF, which previously had been found to be present in high levels in specimens of human cervical cancer.

They reported in the October 29, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that the molecular activity of asTF differed substantially from that of native TF. More...
The modified TF was shown to bind to surface molecules called integrins on endothelial cells, which induced signaling cascades that triggered angiogenesis. Integrins are receptors that mediate attachment between a cell and the tissues surrounding it, which may be other cells or the extracellular matrix (ECM). They also play a role in cell signaling and thereby define cellular shape, mobility, and regulate the cell cycle. Increased interaction between asTF and integrins resulted in increased cell adhesion, cell migration, and development of new blood vessels in both cellular and animal models.

"This is an important breakthrough in cancer research because we are able to draw a more complete molecular picture of how Tissue Factor contributes to cancer growth," explained contributing author Dr. Vladamir Bogdanov, professor of hematology at the University of Cincinnati. "This will help translate basic research into real-life for therapies targeted to stop angiogenesis."

"Our findings introduce a whole new way of studying how the Tissue Factor gene influences tissue formation process, including angiogenesis," said Dr. Bogdanov. "This is another level of understanding the molecular actions behind Tissue Factor."

The investigators anticipate that these studies will encourage development of new ways to target specific forms of Tissue Factor to stop cancerous cell growth while causing minimal impact on the body's capability to stop bleeding.

Related Links:
University of Cincinnati
Leiden University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.